Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CCR2 | P41597 | 1/20 | 0.31 |
| ▸ | BUB1 | O43683 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28009383 | 0.74 | MAPK1 (0.39) | MAPK1HRH3GAABUB1 | |
| SCHEMBL186721 | 0.72 | HRH3 (0.51) | MAPK1HRH3GAA | |
| SCHEMBL1295721 | 0.72 | HRH3 (0.51) | MAPK1HRH3GAA | |
| SCHEMBL28492122 | 0.72 | HRH3 (0.51) | MAPK1HRH3GAA | |
| SCHEMBL14718807 | 0.72 | MAPK1 (0.40) | MAPK1GAA | |
| SCHEMBL27498056 | 0.72 | CCR2 (0.44) | CCR2 | |
| SCHEMBL28807842 | 0.71 | MAPK1 (0.37) | MAPK1HRH3GAABUB1 | |
| SCHEMBL583322 | 0.71 | HRH3 (0.45) | MAPK1HRH3GAA | |
| SCHEMBL6436697 | 0.71 | HRH3 (0.45) | MAPK1HRH3GAA | |
| SCHEMBL15975247 | 0.71 | HRH3 (0.45) | MAPK1HRH3GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | NEITZEL MARTIN | 2011-09-01 | — | — | US | disclosed |
| US-7939657-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2011-05-10 | — | — | US | disclosed |
| US-7569562-B2 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2009-08-04 | — | — | US | disclosed |
| EP-1838701-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | Elan Pharmaceuticals Inc. (US) | 2007-10-03 | — | — | EP | disclosed |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | ELAN PHARMACEUTICALS, INC. | 2007-08-16 | — | — | US | disclosed |
| US-7208488-B2 | N-substituted benzene sulfonamides | ELAN PHARMACEUTICALS, INC. (US) | 2007-04-24 | — | — | US | disclosed |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | ELAN PHARMACEUTICALS, INC. | 2006-11-30 | — | — | US | disclosed |
| WO-2006078753-A1 | N-SUBSTITUTED HETEROCYCLIC SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-1680406-A1 | N-SUBSTITUTED BENZENE SULFONAMIDES | Elan Pharmaceuticals, Inc. (US) | 2006-07-19 | — | — | EP | disclosed |
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | ELAN PHARMACEUTICALS, INC. | 2005-07-28 | — | — | US | disclosed |
| WO-2005042489-A1 | N-SUBSTITUTED BENZENE SULFONAMIDES | ELAN PHARMACEUTICALS, INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050165003-A1 | Treating Alzheimer's Disease; 4-Chloro-N-(4-hydroxy-3-methoxy-benzyl)-N-(2-oxo-azepan-3-yl)-benzenesulfonamide for example; gamma secretase inhibitors; inhibition of beta-amyloid synthesis with minimal inhibition of Notch Signaling | BACE1, PSEN1, BACE2 | MAPK1 1741/4885HRH3 223/4885GAA 746/4885 |
| US-20070191341-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | MAPK1 3131/4885HRH3 120/4885GAA 1658/4885 |
| US-20060270657-A1 | N-substituted heterocyclic sulfonamides | SULT2A1, PSEN1, PSEN2 | MAPK1 3258/4885HRH3 293/4885GAA 715/4885 |
| US-20110212920-A1 | N-Substituted Benzene Sulfonamides | PSEN1, PSEN2, BACE1 | MAPK1 3131/4885HRH3 120/4885GAA 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.